A 5‐year controlled randomized study of prevention of postmenopausal trabecular bone loss with nasal salmon calcitonin and calcium

Abstract. The aim of this paper was to evaluate the long‐term (5 years) efficacy of nasal salmon calcitonin in prevention of trabecular postmenopausal bone loss, which was a follow‐up of a previously published study (3 years); a randomized, controlled group comparison. One hundred healthy postmenopausal women were randomly chosen from those (186) having completed the 3 year protocol. The 100 women were allocated to an additional 2 year period (total of 5 years) of treatment with either 500 mg d‐1, 5 days week‐1 of calcium or the same amount of calcium plus 50 IU d‐1, 5 days per week of nasal salmon calcitonin, 87 (87%) women complied with the protocol throughout. The main outcome measures were the bone mineral density of the lumbar spine (1‐BMD) (DPA) and biochemical parameters reflecting bone turnover (serum alkaline phosphatases, urinary calcium/creatinine and hydroxyproline/creatinine ratios). The women receiving calcium alone presented a significant decrease in 1‐BMD after 6 months [– 1·6 (0·5)%] [mean(SEM)] (P < 0·01) and this decrease remained significant after 36 months [– 6·1(0·8)%] (P < 0·01) and until the end of the trial [– 6·6(1·0)% at t60] (P < 0·01). In women receiving calcium and calcitonin, 1‐BMD significantly increased after 36 months [+ 2(0·7%] (P < 0·01) and 42 months [+ 2·5(0·7)%] (P < 0·01) and was unchanged at the other times of investigation [+ 1·1(1·1)% at t60] (NS). The evolution of BMD in the two groups was highly significantly different (P < 0·001) since the sixth month of the study and remained so until the end of the study. No differences were observed in the biochemical parameters reflecting bone turnover. Nasal administration of salmon calcitonin, using a low‐dose (50 IU d‐1), intermittent (5 days week‐1) regimen, may totally prevent postmenopausal bone loss, at the level of the lumbar spine, for at least 5 years, if the treatment is continued for this duration. It is not clear whether the results observed during the fourth and fifth years are fully attributable to calcitonin or if calcium by itself plays also a protective role against trabecular bone loss.

[1]  J. Reginster,et al.  Long‐term (3 years) prevention of trabecular postmenopausal bone loss with low‐dose intermittent nasal salmon calcitonin , 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[2]  J. Reginster Effect of calcitonin on bone mass and fracture rates. , 1991, The American journal of medicine.

[3]  B. Dawson-Hughes,et al.  A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women , 1991, The New England journal of medicine.

[4]  C. Christiansen,et al.  Dose-response bioactivity and bioavailability of salmon calcitonin in premenopausal and postmenopausal women. , 1991, The Journal of clinical endocrinology and metabolism.

[5]  B. Riis,et al.  Effect of salcatonin given intranasally on early postmenopausal bone loss. , 1989, BMJ.

[6]  P. Geusens,et al.  In vivo long-term precision of spinal bone mass measurement by dual photon absorptiometry. , 1989, Bone and mineral.

[7]  C. Christiansen,et al.  NASAL CALCITONIN FOR TREATMENT OF ESTABLISHED OSTEOPOROSIS , 1989, Clinical endocrinology.

[8]  J. Reginster,et al.  Relationship between whole plasma calcitonin levels, calcitonin secretory capacity, and plasma levels of estrone in healthy women and postmenopausal osteoporotics. , 1989, The Journal of clinical investigation.

[9]  J. Reginster,et al.  One year's treatment of paget's disease of bone by synthetic salmon calcitonin as a nasal spray , 1988, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[10]  J. Reginster,et al.  1-YEAR CONTROLLED RANDOMISED TRIAL OF PREVENTION OF EARLY POSTMENOPAUSAL BONE LOSS BY INTRANASAL CALCITONIN , 1987, The Lancet.

[11]  W. Rostène,et al.  Down-regulation of rat kidney calcitonin receptors by salmon calcitonin infusion evidenced by autoradiography. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[12]  J. Devogelaer,et al.  New modes of administration of salmon calcitonin in Paget's disease. Nasal spray and suppository. , 1987, Clinical orthopaedics and related research.

[13]  J. Kanis,et al.  Long-term follow-up observations on treatment in Paget's disease of bone. , 1987, Clinical orthopaedics and related research.

[14]  J. Reginster,et al.  Assessment of the biological effectiveness of nasal synthetic salmon calcitonin (SSCT) by comparison with intramuscular (i.m.) or placebo injection in normal subjects. , 1987, Bone and mineral.

[15]  P Geusens,et al.  Age-, sex-, and menopause-related changes of vertebral and peripheral bone: population study using dual and single photon absorptiometry and radiogrammetry. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  J. Body,et al.  Plasma calcitonin in primary hyperparathyroidism: failure of C-cell response to sustained hypercalcemia. , 1986, The Journal of clinical endocrinology and metabolism.

[17]  J. Reginster,et al.  Side effects of synthetic salmon calcitonin given by intranasal spray compared with intramuscular injection. , 1985, Clinical and experimental rheumatology.

[18]  Gary O. Zerbe,et al.  Randomization Analysis of the Completely Randomized Design Extended to Growth and Response Curves , 1979 .

[19]  B. Nordin DIAGNOSTIC PROCEDURES IN DISORDERS OF CALCIUM METABOLISM , 1978, Clinical endocrinology.

[20]  L. Avioli,et al.  Effects of prolonged thyrocalcitonin administration on Paget's disease of bone. , 1970, The New England journal of medicine.

[21]  D. Seligson,et al.  A new "kinetic" method for enzyme analysis suitable for automation. , 1969, Clinical chemistry.

[22]  A. Jansen,et al.  Effects of calcitonin on patients with Paget's disease, thyrotoxicosis, or hypercalcaemia. , 1968, Lancet.

[23]  C. Lozano-Tonkin [Diagnostic procedure in disorders of calcium metabolism]. , 1966, Deutsches medizinisches Journal.

[24]  D. Copp,et al.  Evidence for calcitonin--a new hormone from the parathyroid that lowers blood calcium. , 1962, Endocrinology.

[25]  J. Reginster,et al.  Relation between calcium intake during different periods of life and bone mineral content at the menopause , 1992 .

[26]  S. Pors Nielsen,et al.  Measurement of bone mineral content (BMC) of the lumbar spine, I. Theory and application of a new two-dimensional dual-photon attenuation method. , 1980, Scandinavian journal of clinical and laboratory investigation.

[27]  Wilfrid Joseph Dixon,et al.  Introduction to statistical analysis, 2nd ed. , 1957 .